Episode Details
Back to EpisodesAdjuvant and Neoadjuvant Therapy for NSCLC: Who to Treat and With What Agent
Published 3 years, 10 months ago
Description
Listen in as Roy Herbst, MD, PhD, shares with Robert Figlin, MD, how he approaches treatment for patients with early-stage non-small cell lung cancer after the ADAURA and CHECKMATE-816 trials. They discuss different factors that influence use of adjuvant and neoadjuvant treatments, including stage, EGFR mutation status, and PD-L1 status.